North America Injectable Drug Delivery Market

North America Injectable Drug Delivery Market Size (2024 to 2029)

The size of the North America Injectable Drug Delivery Market was valued at USD 1754.89 million in 2024. It is further estimated to be growing at a CAGR of 11.09% and worth USD 2969.10 million by 2029.

The market for injectable medication delivery would expand due to the growing need and demand for patient compliance with treatment. The rising demand for vaccines, insulin, human growth hormone, and many other modern medicines used to treat cancer and other chronic diseases, as well as rising levels of investment in advanced technology, spending on pharma medicines, and growth in the biologics market, will likely accelerate the growth of the injectable drug delivery market in North America region. Because of the effective and focused medication release and low side effects on the body, the Injectable drug delivery market is primarily driven by rising occurrences of chronic diseases in this region. In addition, smart devices that measure dosage and time and additional features like reminders and automated dose changes can help enhance treatment adherence and compliance even further.

The North American injectable drug delivery market achieves a wide scope of development and lucrative outcome via innovations, technical advancements, and marketing of new products driven by major manufacturers. Furthermore, there is a growing emphasis on product safety, efficacy, and patient-friendliness. The injectable medication delivery market would expand in the next few years due to the need for improved technologies to meet the rising demand for regular injectable medicines to treat chronic diseases. Cancer and heart disease were responsible for around 48 percent of all fatalities. It was also revealed that almost half of all individuals in the United States had one or more chronic conditions, with one out of every four having more than two. The rising prevalence of chronic diseases is expected to contribute to the growth of the injectable drug delivery technology market in the forecast period, given the high adoption rate of injectable drug delivery devices among the population suffering from diabetes and heart-related disorders.

With the rising number of needle-related injuries and infections, individuals are becoming less willing to utilize injections, restricting the growth of the North American injectable drug delivery technology market. In addition, the industry is also facing challenges by the growing use of alternate medication delivery techniques and safety issues connected with injections.

This research report on the North America Injectable Drug Delivery Market has been segmented and sub-segmented into the following categories.

North America Injectable Drug Delivery Market Analysis By Device Type

• Self-Injection Devices
• Conventional Devices

North America Injectable Drug Delivery Market Analysis By Formulation

• Conventional Drug Delivery
• Novel Drug Delivery

North America Injectable Drug Delivery Market Analysis By Therapeutic Use

• Autoimmune Disorders
• Hormonal Disorders
• Oncology

North America Injectable Drug Delivery Market Analysis By End User

• Hospitals
• Homecare Settings
• Research Institutes
• Clinical Laboratories

North America Injectable Drug Delivery Market Analysis By Country

• The United States
• Canada
• Rest of North America

Geographically, Because of the growing diagnosis and treatment of chronic illnesses in these areas, North America accounted for the largest proportion of the worldwide injectable drug delivery market. Increased R&D expenditure and rising healthcare spending are some of the reasons driving the injectable medication delivery market in these regions. Because of the rising prevalence of cardiovascular illnesses, the expanding elderly population, and the strong presence of industry players in that area, the United States injectable drug delivery technology market held the highest market share in North America in 2023. A significant driver driving regional market expansion is the increased use of new injectable medication delivery systems among diabetes, cancer, and other autoimmune disease patients in North America. Furthermore, these injectables' convenience and therapeutic advantages are driving demand, allowing North America to capture the largest share of the global market.

KEY MARKET PLAYERS

Some of the major companies dominating the North America Injectable drug delivery market profiled in the report are Antares Pharmaceuticals Ltd, Baxter International, Becton Dickinson Company, Elcam Medical, Eli Lily and Company, Unilife Corporation, and West Pharmaceutical Inc.